Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort

OBJECTIVE: Benefits and risks of new therapies in Multiple Sclerosis (MS) must be balanced carefully and tailored to patients. We aimed to describe our experience with Fingolimod (FTY), correlating demographics, clinical and hematological features of the Relapsing MS (RMS) cohort with the occurring...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Brain Behav
Asıl Yazarlar: Manni, Alessia, Direnzo, Vita, Iaffaldano, Antonio, Di Lecce, Valentina, Tortorella, Carla, Zoccolella, Stefano, Iaffaldano, Pietro, Trojano, Maria, Paolicelli, Damiano
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651388/
https://ncbi.nlm.nih.gov/pubmed/29075564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.804
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller